ENTITY
Ocumension

Ocumension (1477 HK)

55
Analysis
Industrials • China
Ocumension is a China-based ophthalmic pharmaceutical platform company focused on discovering, developing, and commercializing first- or best-in-class ophthalmic therapies. Its product portfolio addresses various eye diseases, including uveitis, dry eye, glaucoma, and macular degeneration. The company was founded in 2017 and is headquartered in Suzhou, China.
more
•12 Jul 2020 15:57

ECM Weekly (12 July 2020) - Ocumension and Smoore, Simcere, Blue Moon, Weihai City Bank, Radiance

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. Hong...

Share
bullish•Ocumension
•09 Jul 2020 13:29

Ocumension Therapeutics IPO: Trading Debut

Ocumension Therapeutics (1477 HK) is a China-based ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing...

Logo
544 Views
Share
bullish•Ocumension
•09 Jul 2020 11:07

Ocumension (欧康结视) IPO Trading: Share Could Double Thanks to Record Demand

Ocumension raised HKD 1,424 million (USD 183 m) from its global offering and will list on the Hong Kong Stock Exchange tomorrow. In our previous...

Logo
591 Views
Share
•05 Jul 2020 09:36

ECM Weekly (4 July 2020) - Smoore, Ocumension, Zhenro Services, Archosaur Games

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. It...

Share
bullish•Ocumension
•30 Jun 2020 20:49

Ocumension Therapeutics IPO: Valuation Insights

Ocumension Therapeutics (1477 HK) is a China-based ophthalmic pharmaceutical company dedicated to identifying, developing and commercializing...

Logo
735 Views
Share
x